DLA Class II Alleles Are Associated with Risk for Canine Symmetrical Lupoid Onychodystropy (SLO) by Wilbe, Maria et al.
DLA Class II Alleles Are Associated with Risk for Canine
Symmetrical Lupoid Onychodystropy (SLO)
Maria Wilbe













1Department of Animal Breeding and Genetics, Biomedical Centre, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden, 2Fredrikstad Dyrehospital, Gamle
Fredrikstad, Norway, 3Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden, 4Department of Clinical Sciences,
Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden, 5Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden,
6Broad Institute, Cambridge, Massachusetts, United States of America, 7Department of Basic Sciences and Aquatic Medicine, Norwegian School of Veterinary Science,
Oslo, Norway
Abstract
Symmetrical lupoid onychodystrophy (SLO) is an immune-mediated disease in dogs affecting the claws with a suggested
autoimmune aethiology. Sequence-based genotyping of the polymorphic exon 2 from DLA-DRB1, -DQA1, and -DQB1 class II
loci were performed in a total of 98 SLO Gordon setter cases and 98 healthy controls. A risk haplotype (DRB1*01801/
DQA1*00101/DQB1*00802) was present in 53% of cases and 34% of controls and conferred an elevated risk of developing
SLO with an odds ratio (OR) of 2.1. When dogs homozygous for the risk haplotype were compared to all dogs not carrying
the haplotype the OR was 5.4. However, a stronger protective haplotype (DRB1*02001/DQA1*00401/DQB1*01303,
OR=0.03, 1/OR=33) was present in 16.8% of controls, but only in a single case (0.5%). The effect of the protective
haplotype was clearly stronger than the risk haplotype, since 11.2% of the controls were heterozygous for the risk and
protective haplotypes, whereas this combination was absent from cases. When the dogs with the protective haplotype were
excluded, an OR of 2.5 was obtained when dogs homozygous for the risk haplotype were compared to those heterozygous
for the risk haplotype, suggesting a co-dominant effect of the risk haplotype. In smaller sample sizes of the bearded collie
and giant schnauzer breeds we found the same or similar haplotypes, sharing the same DQA1 allele, over-represented
among the cases suggesting that the risk is associated primarily with DLA-DQ. We obtained conclusive results that DLA class
II is significantly associated with risk of developing SLO in Gordon setters, thus supporting that SLO is an immune-mediated
disease. Further studies of SLO in dogs may provide important insight into immune privilege of the nail apparatus and also
knowledge about a number of inflammatory disorders of the nail apparatus like lichen planus, psoriasis, alopecia areata and
onycholysis.
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Introduction
Canine symmetrical lupoid onychodystrophy (SLO) is described
as separation and sloughing of several claws from claw beds and
ultimately affecting all claws. The pathogenesis of SLO is
incompletely elucidated, but allergic, infectious and immune-
mediated diseases have all been associated with symmetrical
onychomadesis [1]. Thus, the lupoid reaction observed histopath-
ologically and the clinical signs of onychomadesis represent an
immune-mediated disease of the claw, rather than an actual
triggering event of the disease. Initially, separation of claw from
claw bed and subsequent sloughing is noted on one or more claws,
but within two to three months all claws might be affected. Re-
growth results in dystrophic claws, brittle, crumbling and
misshapen claws [2]. A thorough clinical investigation is important
for a correct diagnosis [3]. Histopathology of affected claws
present infiltrates of mononuclear cells, apoptosis of the epidermal
basal cells and hydropic degeneration of the epidermal basal cells.
Typically the inflammatory infiltrate forms a parallel band to the
basement membrane called lichenoid pattern. Pigmentary incon-
tinence is also often observed in the dermis [4]. Treatment with
immunosuppressive drugs, such as glucocorticoids, has been
reported to be successful [5] as well as fatty acid supplementation
[6] suggesting an autoimmune aethiology of the disease.
The genomic structure in the dog is unique, with long haplotype
blocks and extensive linkage disequilibrium. Dog and human share
a similar set of orthologous genes, lives in the same environment
and are affected by diseases of similar aethiology. Therefore, the
dog is an excellent model for studies on genetic diseases [7–9].
Autoimmune diseases in humans have complex patterns of
inheritance [10]. In humans, several keratin disorders exist with
similarities to SLO [11]. Inflammatory diseases of the nail are
common. This includes the group of non-infectious inflammatory
disorders of the nail apparatus like psoriasis,lichen planus and other
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erythema multiforme [12]. Nail changes in lupus erythematosus are
not common, but in acute lupus erythematosus, onycholysis is the
most common symptom. Nail loss is uncommon but has been
observed. Lichen planus is affecting the nail more often than lupus
erythematosus and may lead to complete nail loss, either insidiously
or relatively rapidly in case of ulcerating lichen planus [12]. In dogs,
SLO is a significant health concern and appears to be the most
common immune-mediated claw disease [4]. Particularly high
disease prevalence has been reported in certain breeds such as
Gordon setters (12.6%) [13], [2]. English setters, giant schnauzers
(10%) and also bearded collies are reported to havea high incidence
of SLO (unpublished observation). The increased risk in specific
breeds suggests a significant genetic component, influencing the
power of mapping the genetic risk factors underlying SLO. The
inheritance of the disease has not been reported but is suggested to
be complex. Studies on pedigrees, indicate large differences in
incidence between breeding lines and an increased risk in relatives
of affected dogs (unpublished observation) supporting a high
heritability for the diseases.
In the dog, the major histocompatibility complex (MHC) class II
is called DLA (dog leukocyte antigen) class II and consists of three
highly polymorphic genes known as DLA-DRB1, DLA-DQA1 and
DLA-DQB1 and one monomorphic gene, DLA-DRA [14], [15].
Due to the high linkage disequilibrium in the region and the
extensive polymorphism in exon 2 (which encodes the antigen-
binding domain), genetic typing of this exon is likely to detect most
of the variation in the locus. There are currently 106 DLA-DRB1,
26 DLA-DQA1 and 62 DLA-DQB1 alleles identified in the dog
[15]. The DLA class II genes are in high linkage disequilibrium
(LD). However, the extension of LD within this region remains
unknown. Many previous studies have identified DLA class II as a
geneticriskorprotectivefactorforvariousautoimmune orimmune-
mediated diseases in dogs [16-22]. In humans the association to
MHC class II is also well established in autoimmune diseases [16].
The aim of this study was to elucidate the potential associations
between DLA class II and risk of developing SLO.
Results
Haplotypes, alleles and genotypes
In 196 Gordon setters, a total of 10 different DLA-DRB1/
DQA1/DQB1 haplotypes were identified. The majority of the
dogs (43.4%) carried haplotype DRB1*01801/DQA1*00101/
DQB1*00802. The other nine haplotypes ranged in frequencies
between 0.3–12.8% (Table 1). Also, 10 DRB1 alleles, six DQA1
alleles and eight DQB1 alleles were found in the population
(Table 2). DRB1*01801 was the most common allele with a
frequency of 43.4 % and the other nine DRB1 alleles had
frequencies between 0.3–12.8%. 74.2% of Gordon setters had
allele DQA1*00101 and the other alleles ranged in frequency
between 0.3–11.2%. Eight DQB1 alleles were found with
DQB1*00802 being the most common (43.4%) and the others
in frequencies between 0.3–25.0%. We also identified 34 different
genotypes (haplotype combinations) with frequencies between 0.5–
18.9% (Table S1).
Five haplotypes were found in the 10 bearded collies. The two
most common, DRB1*01801/DQA1*00101/DQB1*00802 and
DRB1*01801/DQA1*00101/DQB1*00201 had frequencies of
50% and 30%, respectively. The other haplotypes ranged in
frequencies between 5–10% (Table S2). There were three DRB1
alleles (*01801, *00201 and *01501) and three DQA1 alleles
(*00101, *00901 and *00601). Five DQB1 alleles were identified.
Two were common (30–50%) and three were rare (5–10%) (Table
S3). A total of four different genotypes were found (Table S1).
In the 110 giant schnauzers, we identified 10 haplotypes. Four
were common (13.6–23.6%) and six were rare (0.5–9.%) (Table
S4). We also identified eight DRB1 alleles, four DQA1 alleles and
six DQB1 alleles (Table S5). We found 32 genotypes (frequencies
of 0.9–10.0%) (Table S1).
Disease association
In Gordon setters, two haplotypes differed markedly in
frequency between cases and controls. The haplotype
DRB1*01801/DQA1*00101/DQB1*00802 occurred in 52.6%
of the cases compared to 34.2% of the controls (OR=2.1,
p,0.001) and was defined as a risk-haplotype. This haplotype was
also the most common haplotype in the Gordon setter population
(43.4%). The allele frequencies of each of the genes involved in the
risk haplotype were higher in cases compared to controls and
showed a significant disease association (DRB1*01801: 52.6% vs.
34.2%, OR=2.1, p,0.001; DQA1*00101: 83.7% vs. 64.8%,
OR=2.8, p#0.001 and DQB1*00802: 52.6% vs. 34.2%
OR=2.1, p#0.001). All of these alleles are the most common
alleles in the population with frequencies of 43.4%, 74.2% and
43.3% (DRB1/DQA1/DQB1, respectively).
Table 1. Haplotype frequencies in Gordon setter.
Number Haplotype DRB1/DQA1/DQB1 Total population % (392) Cases % (196) Controls % (196)
1 01801/00101/00802 43.4 (170) 52.6 (103) 34.2 (67)
2 01501/00601/02301 4.6 (18) 2.6 (5) 6.6 (13)
3 1800103/00101/00201 8.2 (32) 8.2 (16) 8.2 (16)
4 00101/00101/00201 12.8 (50) 15.3 (30) 10.2 (20)
5 02001/00401/01303 8.7 (34) 0.5 (1) 16.8 (33)
6 04901/01001/01901 11.2 (44) 12.8 (25) 9.7 (19)
7 00901/00101/008011 5.9 (23) 1.5 (3) 10.2 (20)
8 00601/005011/00701 0.3 (1) 0.0 (0) 0.5 (1)
9 00501/00301/00501 1.0 (4) 0.5 (1) 1.5 (3)
10 10102/00101/00201 4.1 (16) 6.1 (12) 2.0 (4)
A total of 10 different haplotypes were found. DRB1*01801/DQA1*00101/DQB1*00802 had an increased frequency in cases and DRB1*02001/DQA1*00401/DQB1*01303
was significantly more frequent in controls, both numbers shown in bold.
doi:10.1371/journal.pone.0012332.t001
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carrying haplotype DRB1*02001/DQA1*00401/DQB1*01303.
This haplotype is rare in the population (8.7%) and was found in
16.8% of the controls compared to 0.5% of the cases (OR=0.03,
p#0.0001) and thus is significantly associated with protection
against disease development. Calculation of the allele frequencies
at each of the three loci separately showed the same results, as
these alleles were unique to this haplotype.
Gordon setter dogs homozygous for the risk haplotype,
DRB1*01801/DQA1*00101/DQB1*00802 had even higher odds
for developing disease. In fact, 18.9% in the population was
homozygous for this risk haplotype, which was found in 28.6% of
cases compared to 9.2% of controls (OR=4.0, p=0.001 None of
the 11 dogs heterozygous for the risk and the protective haplotypes
had SLO, emphasizing the strength of the protective allele
(Table 3).
We also compared the dogs homozygous for risk haplotype vs.
those not carrying this haplotype (OR=5.41, p=0.0004) and vs.
heterozygous for risk haplotype (OR=3.24, p=0.01) and finally
heterozygous for risk haplotype vs. not carrying risk haplotype
(OR=1.67, p=0.17) (Table 4). However, when the protective
haplotype was removed from the analysis, the odds ratio for
homozygosity for the risk haplotype vs. all without risk alleles was
2.97 (Table 4), for homozygotes vs. heterozygotes the OR was 2.52
and for heterozygotes vs. no risk the OR was 1.18 although none
of these results were significant based on the smaller sample size.
Comparative analysis between breeds
Bearded collies and giant schnauzers were analyzed for
comparative purposes, despite small sample numbers. Interesting-
ly, the risk haplotype found in Gordon setter (DRB1*01801/
DQA1*00101/DQB1*00802) was also found in increased fre-
quency among the bearded collie cases (cases 40% vs. controls
20%). A similar haplotype (DRB1*01801/DQA1*00101/
DQB1*00202), where only the DQB1 allele differs from the risk
haplotype was also identified (cases 60% vs. controls 40%). These
two haplotypes are the only ones occurring in cases, whereas in
controls, three more haplotypes exists. When evaluating the alleles
it appears that all bearded collie cases carry DRB1*01801 and
DQB1*00101, further supporting the findings in Gordon setter.
In giant schnauzer we observed a higher number of possible
cases carrying haplotype DRB1*00101/DQA1*00101/
DQB1*00201 compared to controls (26.9% vs. 15.0%). This risk
haplotype of DRB1 and DQB1 differs from Gordon setter and








01801 43.4 (170) 52.6 (103) 34.2 (67)
01501 4.6 (18) 2.6 (5) 6.6 (13)
1800103 8.2 (32) 8.2 (16) 8.2 (16)
00101 12.8 (50) 15.3 (30) 10.2 (20)
02001 8.7 (34) 0.5 (1) 16.8 (33)
04901 11.2 (44) 12.8 (25) 9.7 (19)
00901 5.9 (23) 1.5 (3) 10.2 (20)
00601 0.3 (1) 0.0 (0) 0.5 (1)
00501 1.0 (4) 0.5 (1) 1.5 (3)
10102 4.1 (16) 6.1 (12) 2.0 (4)
DQA1
00101 74.2 (291) 83.7 (164) 64.8 (127)
00601 4.6 (18) 2.6 (5) 6.6 (13)
00401 8.7 (34) 0.5 (1) 16.8 (33)
01001 11.2 (44) 12.8 (25) 9.7 (19)
005011 0.3 (1) 0.0 (0) 0.5 (1)
00301 1.0 (4) 0.5 (1) 1.5 (3)
DQB1
00802 43.4 (170) 52.6 (103) 34.2 (67)
02301 4.6 (18) 2.6 (5) 6.6 (13)
00201 25.0 (98) 29.6 (58) 20.4 (40)
01303 8.7 (34) 0.5 (1) 16.8 (33)
01901 11.2 (44) 12.8 (25) 9.7 (19)
008011 5.9 (23) 1.5 (3) 10.2 (20)
00701 0.3 (1) 0.0 (0) 0.5 (1)
00501 1.0 (4) 0.5 (1) 1.5 (3)
Altogether, 10 DRB1 alleles, six DQA1 alleles and eight DQB1 alleles were found
in the population. The alleles DRB1*01801, DQA1*00101 and DQB1*00802 was
observed in a higher frequency in cases while the alleles DRB1*02001,
DQA1*00401and DQB1*01303 was more frequent in controls. Numbers in bold
indicate significant different between cases and controls.
doi:10.1371/journal.pone.0012332.t002
Table 3. Haplotypes, alleles and genotypes in Gordon setter cases and controls.
Haplotype, allele or genotype Total population % (392) Cases % (196) Controls % (196) OR P-value 99% CI
01801/00101/00802 43.4 (170) 52.6 (103) 34.2 (67) 2.1 0.0004 1.3–3.6
02001/00401/01303 8.7 (34) 0.5 (1) 16.8 (33) 0.03 0.0001 0.002–0.35
DRB1*01801 43.4 (170) 52.6 (103) 34.2 (67) 2.1 0.0004 1.25–3.64
DRB1*02001 8.7 (34) 0.5 (1) 16.8 (33) 0.03 ,.0001 0.002–0.35
DQA1*00101 74.2 (291) 83.7 (164) 64.8 (127) 2.8 ,.0001 1.48–5.23
DQA1*00401 8.7 (34) 0.5 (1) 16.8 (33) 0.03 ,.0001 0.002–0.35
DQB1*00802 43.4 (170) 52.6 (103) 34.2 (67) 2.1 0.0004 1.25–3.64
DQB1*01303 8.7 (34) 0.5 (1) 16.8 (33) 0.03 ,.0001 0.002–0.35
Genotype 1 18.9 (37) 28.6 (28) 9.2 (9) 3.96 0.001 1.36–11.52
Genotype 5 5.6 (11) 0 (0) 11.2 (11) 0 0.002 0
Odds ratio (OR) and Yates p-values were calculated for differences greater than 10% between cases and controls. A 99% confidence interval (CI) was used.
doi:10.1371/journal.pone.0012332.t003
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haplotype found in Gordon setter and bearded collie further
supporting the findings in these breeds. When DQA1*00101 was
analyzed separately in giant schnauzer it was not significantly
associated with an increased risk. We also identified a protective
haplotype, DRB1*01301/DQA1*00301/DQB1*00501 in giant
schnauzer.
Discussion
In the present study we have evaluated the association of MHC
class II haplotypes and alleles with symmetrical lupoid onycho-
dystrophy in a large cohort of Gordon setter and smaller numbers
from two additional breeds of dogs, the giant schnauzer and the
bearded collie. The analysis revealed that DLA class II is
significantly associated with SLO and provides support for the
hypothesis of SLO being an immune-mediated disease. Genetic
association between DLA and SLO and similar claw conditions
has been established in all the breeds analyzed here even if the
number of dogs studied and the level of significance varied
between breeds. We found that dogs homozygous for the risk
haplotype had elevated risk of 2.97 of developing SLO, but that a
rare protective haplotype had a stronger 33-fold protective effect.
The protective haplotype had an uneven distribution between
cases and controls and only three (10%) of the controls were
homozygous. Because 90% of the controls were heterozygotes,
including 11 (37%) heterozygotes for the combination of risk and
protective haplotypes, the results indicate a dominant effect of the
protective haplotype. It is worth emphasizing the very high OR of
93.3 when comparing dogs homozygous for the risk haplotype vs.
dogs with at least one protective haplotype, even if the observed
number of the protective haplotype is low in cases (Table 4).
The relatively high frequency of dogs homozygous for DLA
class II haplotypes, provides a unique opportunity to estimate an
unbiased risk effect of the most common haplotypes, and to
compare homozygote vs. heterozygote dogs. In humans, homo-
zygosity for HLA haplotypes is extremely rare, preventing analyses
of genetic risk association between MHC class II and immune-
mediated disease in homozygotes. The comparison of OR
depending on the presence of two (homozygous) or one
(heterozygous) risk haplotype should be carefully interpreted
(Table 4). Comparison of the group of dogs being homozygous
for the risk haplotype to those with no risk haplotype (OR=5.41),
to the heterozygotes (OR=3.24) and the heterozygotes versus
those with no risk (OR=1.67) could indicate a co-dominant effect
of the risk haplotype.
When we compared the SLO risk haplotype in the Gordon
setter, with those of the bearded collie and the giant schnauzer, we
observed that the DRB1-DQA1-DQB1 haplotypes were relatively
similar although the sample number was small. Even if there were
some differences, all the major risk haplotypes in the three breeds
contained the same DQA1 allele. Strikingly, the DQA1*00101
molecule associated with SLO has an Arg at position 55 instead of
an Asp as well as (DQA1*00601, *00901, *01001, *01301, *01401
and *01501). Kennedy et al suggested that this amino acid is likely
to be important for peptide binding to the canine DQ class II
molecule [23], but this remains to be verified. One might speculate
that some antigenic peptides bound by the Arg containing DQ
molecules leads to increased risk of aberrant immune responses
ultimately leading to de-regulated immunity and disease. The
exact type of immune-mediated mechanism involved in develop-
ment of SLO remains to be established. In several human
autoimmune diseases, MHC class II-mediated autoantigen
presentation leads to broken tolerance and similar mechanisms
are likely to operate during SLO progression.
MHC class II-mediated autoantigen presentation leading to
broken tolerance is likely to operate during SLO progression. The
autoantigen/s involved in SLO remains to be defined. Identifica-
tion of such antigens could lead to increased understanding of
similar diseases in human.
The human hair follicles and the nail apparatus is reported to
harbour an unusual site of immune reactions called immune
privilege [24], originally described as sites providing a relative
protection against rejection of transplants [25]. There are strong
indications that parts of the hair follicle and nail epithelium is
Table 4. Comparison of OR for SLO depending on the number of risk haplotypes.
Haplotype Cases (n) Controls (n) OR Yates P-value 99% CI
Homozygous risk 28 9 5.41 0.0003 1.64–17.88
No risk 23 40
Homozygous risk 28 9 2.97 0.04 0.84–10.49
No risk - no protection 22 21
Homozygous risk 28 9 3.24 0.01 1.06–9.93
Heterozygous risk 47 49
Homozygous risk 28 9 2.52 0.05 0.81–7.83
Heterozygous risk - no protection 47 38
Heterozygous risk 47 49 1.67 0.17 0.71–3.92
No risk 23 40
Heterozygous risk - no protection 47 38 1.18 0.79 0.045–3.10
No risk - no protection 22 21
Homozygous risk 28 9 93.3 ,. 0001 5.68–1532
Protection 1 30
The difference in OR according to the number of risk haplotypes (homozygous- heterozygous-none). Risk haplotype is DRB1*01801/DQA1*00101/DQB1*00802 and
protective haplotype is DRB1*02001/DQA1*00401/DQB1*01303.
doi:10.1371/journal.pone.0012332.t004
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MHC antigens. These mechanisms remain to be fully understood,
but there are reasons to believe that a disturbance of these
mechanisms may play a key role in the pathogenesis of one of the
most common organ-specific autoimmune diseases, alopecia
areata, which shows frequent nail involvement [12], [24], [26].
In summary, we have identified both a risk haplotype for
developing SLO in Gordon setter and also a haplotype that may
protect dogs from developing SLO. The risk is even higher in dogs
homozygous for the specific risk haplotype. In contrast, dogs
heterozygous for the risk and protective haplotypes are over-
represented among controls suggesting that the protective effect is
phenotypically stronger. To be able to distinguish a potential
functional effect of DRB1*1801 from the closely linked loci in
strong LD, it will be important to type more dogs/breeds to
identify dogs with DRB1*1801. However, other variants of linked
loci, but our findings may provide an impetus for future breeding
practices in an effort to increase the frequency of the protective
haplotype to reduce the incidence of SLO in Gordon setters.
Moreover, canine SLO could provide new information that could
benefit a number of related non-infectious inflammatory disorders
of the nail apparatus in humans including lichen planus, psoriasis,
alopecia areata, pemphigus vulgaris, and onycholysis and provide
new insight in immune privilege of the nail apparatus.
Materials and Methods
Study population
The main study population was based on Gordon setters. A
total of 196 dogs were included, among these, 98 dogs were
classified as SLO cases and 98 as healthy controls. Most of the
cases were unrelated at the grand-parental level. The average age
of cases were 5.6 years of age while the control dogs had an
average age of 10 years (Table S6).
We also used 10 bearded collies and 110 giant schnauzers for
comparative purpose. Five bearded collies were defined as SLO
cases and five as healthy controls. In giant schnauzer, we used 30
healthy controls and 80 dogs classified with different claw
abnormalities. A total of seven SLO cases were identified among
the giant schnauzer population. The age of onset for SLO in both
giant schnauzers and Gordon setters is between two and seven
years of age, with an average of about 4.5 years of age. All the
control dogs used for comparative purpose in this study were older
than seven years of age and unrelated (Table S6).
Clinical examination
The inclusion criteria used for cases were veterinary-verified
diagnosis, where dogs two to seven years of age lost all claws on all
four paws within a short time span. Inclusion criteria for all the
control dogs were that they had never experienced claw disorders
and were more than eight years of age for the Gordon setters and
more than seven years of age for all the other breeds. The giant
schnauzers were classified according to owner’s questionnaire and
grouped according to Table S7.
Isolation of genomic DNA
Genomic DNA from the Gordon setters was extracted using
250 ml EDTA blood using the E.Z.N.A. Blood DNA Kit (Omega
bio-tek, Norcross, GA).
Genomic DNA from bearded collies and giant schnauzers was
extracted from 200 ml EDTA blood by using a standard salt
extraction protocol, the Qiagen QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA).
PCR amplification, DNA Sequencing and data analysis
The methods for amplification, sequencing and data analysis of
DLA-DRB1, -DQA1 and -DQB1 were performed as previously
described [21]. Primer pairs used for amplification of DLA-DRB1,
-DQA1, and -DQB1 was DRB1 (forward): gatccccccgtccccacag,
DRB1 (reverse): cgcccgctgcgctca, DQA1 (forward): taaggtt-
cttttctccctct, DQA1 (reverse): ggacagattcagtgaagaga, DQB1 (for-
ward): ctcactggcccggctgtctc and DQB1 (reverse): cacctcgccgctg-
caacgtg [14]. A T7 tail (taatacgactcactatag) was used to label the
PCR products for sequencing. The purified PCR products were
sequenced using capillary-electrophoresis on an Applied Biosys-
tems 3730. BigDyeH Terminator v3.1 (Applied Biosystems, Foster
City, CA). Finally, the nucleotide sequences for DLA-DRB1,
-DQA1, and -DQB1 were analyzed using MatchTools and
MatchToolsNavigator (Applied Biosystems) also used for assigning
alleles, haplotypes and genotypes. The most frequently occurring
haplotypes could easily be identified in homozygous dogs. Due to
the high frequency of these haplotypes, the probability that they
are present also in heterozygous dogs is high. After thorough
manual checking of each diploid sequence, additional haplotypes
not found in homozygous individuals could be identified by
‘‘subtracting’’ the haplotypes initially identified in homozygotes.
All alleles identified in this study are available in the IPD - MHC
Database (http://www.ebi.ac.uk/ipd/mhc/dla/index.html).
Statistical analyses
Statistical analyses were performed with the statistical pro-
gram VassarStats (http://faculty.vassar.edu/lowry/VassarStats.
html). 262 Contingency tables were used for calculations of Odds
ratio and Yates p-value, which is corrected for continuity. The
number of SLO-cases and controls having each specific allele,
haplotype or genotype compared to the overall number of cases
and controls in dogs not carrying it, was the basis for the OR-
estimates. We also evaluated dogs homozygous for the risk
haplotype vs. dogs heterozygous for the risk haplotype, dogs
homozygous for the risk haplotype vs. the other haplotypes and
dogs heterozygous for the risk haplotype vs. all other haplotypes. A
99% confidence interval (CI) was used for all tests. Statistical
analysis was only performed for Gordon setters, due to an
insufficient number of dogs in bearded collies and uncertain
disease classification in giant schnauzers.
Ethics Statement
Ethical approval for performing this study has been granted by
the Ethical board for experimental animals in Uppsala, Sweden
(Dnr C138/6).
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Table S1 Genotype frequencies in Gordon setter, bearded collie
and giant schnauzer. Genotype 1 in Gordon setter (being
homozygous for DRB1*01801/DQA1*00101/DQB1*00802)
gave an even higher risk for developing SLO and genotype 5
(DRB1*01801/DQA1*00101/DQB1*00802 and DRB1*02001/
DQA1*00401/DQB1*01303) was protective.
Found at: doi:10.1371/journal.pone.0012332.s001 (0.10 MB
DOC)
Table S2 Haplotype frequencies in bearded collie. Only two
different haplotypes were found in cases whereas five were found
in control dogs. Haplotype 1 and 2 occur in higher frequency in
cases compared to controls (not significant).
Found at: doi:10.1371/journal.pone.0012332.s002 (0.03 MB
DOC)
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bearded collies. Altogether, three DRB1, three DQA1 and five
DQB1 alleles were found in the population. Only one DRB1, one
DQA1 and two DQB1 alleles were identified in the cases
compared to three DRB1, three DQA1 and five DQB1 alleles
in control dogs.
Found at: doi:10.1371/journal.pone.0012332.s003 (0.03 MB
DOC)
Table S4 Haplotype frequencies in giant schnauzer. 10 different
haplotypes were identified in the total population. Haplotype
DRB1*00101/DQA1*00101/DQB1*00201, was more common
in cases compared to control dogs. Haplotype DRB1*01301/
DQA1*00301/DQB1*00501 was more frequently occurring in
controls compared to cases.
Found at: doi:10.1371/journal.pone.0012332.s004 (0.04 MB
DOC)
Table S5 DLA DRB1/DQA1/DQB1 allele frequencies in giant
schnauzer. Altogether, eight DRB1 alleles, four DQA1 alleles and
six DQB1 alleles were found in the population. The allele
DRB1*00101 was increased in cases compared to controls. A
protective effect was found for dogs carrying allele DRB1*01301.
Found at: doi:10.1371/journal.pone.0012332.s005 (0.04 MB
DOC)
Table S6 Diagnostic information and DLA-DRB1, -DQA1 and
-DQB1 alleles for all dogs included in the study (Gordon Setter
(GSet), bearded collie (BC) and giant schnauzer (GSch)).
Found at: doi:10.1371/journal.pone.0012332.s006 (0.51 MB
DOC)
Table S7 The inclusion criteria used for giant schnauzers.
Found at: doi:10.1371/journal.pone.0012332.s007 (0.03 MB
DOC)
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